Cardiome's lead drug candidate, vernakalant, is designed to help restore normal heart rhythm for patients who develop atrial arrhythmia (abnormal heartbeat) after surgery, for example. After two successful phase 3 studies, Cardiome and partner Astellas Pharma submitted a New Drug Application to the FDA for an intravenous form of the drug.